Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study

Simple item page
dc.contributor.authorOruc Z.
dc.contributor.authorKaplan M.A.
dc.contributor.authorGeredeli C.
dc.contributor.authorSari N.Y.
dc.contributor.authorOzaslan E.
dc.contributor.authorAytekin A.
dc.contributor.authorElkiran E.T.
dc.contributor.authorKoca S.
dc.contributor.authorDogan M.
dc.contributor.authorTuran N.
dc.contributor.authorYuce O.
dc.contributor.authorSevinc A.
dc.contributor.authorErcelep O.
dc.contributor.authorIsikdogan A.
dc.date.accessioned2024-07-22T08:07:33Z
dc.date.available2024-07-22T08:07:33Z
dc.date.issued2020
dc.description.abstractPurpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients. Methods: A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between 2013-2017 were retrospectively evaluated. Sixteen potential prognostic variables were assessed for analysis. Results: The patients had received a median of 5 prior chemotherapy regimens and a median of 3 eribulin cycles for MBC. Median progression-free survival (PFS) was 5.5 months (95% Cl: 4.1-7.8) and median overall survival (OS) was 11 months (95 % Cl: 6-15). Multivariate analysis showed that eribulin treatment line was shown to have independent prognostic significance for PFS. PFS difference was demostrated in patients who received 3 chemotherapy lines for advanced disease compared to those who had more than 3 chemotherapy lines [median PFS; 3 lines: 8.6 months (6.2-11) and >3 lines: 4.6 months (3.7-4.6) p=0.00]. The clinical benefit rate (CBR) was 52.5 and 35% in patients treated with three lines and with >3 previous chemotherapeutic regimens. Most common toxicities were neutropenia (62.5%), fatigue (52.5%), alopecia (50%) and nausea (37.5%). Conclusions: Eribulin treatment line was identified as indepedent prognostic factor for PFS in MBC patients. © 2020 Zerbinis Publications. All rights reserved.
dc.identifier.issn11070625
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13986
dc.language.isoEnglish
dc.publisherZerbinis Publications
dc.subjectAdult
dc.subjectAged
dc.subjectBreast Neoplasms
dc.subjectFemale
dc.subjectFurans
dc.subjectHumans
dc.subjectKetones
dc.subjectMiddle Aged
dc.subjectPrognosis
dc.subjectRetrospective Studies
dc.subjectaminotransferase
dc.subjectanthracycline derivative
dc.subjectcapecitabine
dc.subjecteribulin
dc.subjectgemcitabine
dc.subjecttaxane derivative
dc.subjectvinorelbine tartrate
dc.subjecteribulin
dc.subjectfuran derivative
dc.subjectketone
dc.subjectadult
dc.subjectaged
dc.subjectalopecia
dc.subjectanemia
dc.subjectarthralgia
dc.subjectArticle
dc.subjectcancer chemotherapy
dc.subjectcancer patient
dc.subjectcancer prognosis
dc.subjectcancer survival
dc.subjectclinical evaluation
dc.subjectclinical outcome
dc.subjectdiarrhea
dc.subjectdrug dose reduction
dc.subjectdrug efficacy
dc.subjectdrug hypersensitivity
dc.subjectdrug safety
dc.subjectfatigue
dc.subjectfebrile neutropenia
dc.subjectfemale
dc.subjecthuman
dc.subjectindependent variable
dc.subjectmajor clinical study
dc.subjectmedian survival time
dc.subjectmetastatic breast cancer
dc.subjectmultiple cycle treatment
dc.subjectnausea
dc.subjectnephrotoxicity
dc.subjectneuropathy
dc.subjectneutropenia
dc.subjectoverall survival
dc.subjectpatient history of chemotherapy
dc.subjectperipheral neuropathy
dc.subjectprogression free survival
dc.subjectreliability
dc.subjectretrospective study
dc.subjectrisk factor
dc.subjectside effect
dc.subjectstomatitis
dc.subjectthrombocytopenia
dc.subjecttreatment response
dc.subjectTurkey (republic)
dc.subjectvomiting
dc.subjectbreast tumor
dc.subjectclinical trial
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectprognosis
dc.titleIs eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu